Background

The current debate about the lower limit of normal (LLN) vs the 0.7 fixed ratio to diagnose COPD is not completely resolved, and little information about the clinical impact of these different criteria is available. We compared differences in health-related quality of life, exacerbations, exercise tolerance, physical activity, comorbidity, and systemic biomarkers of subjects with FEV 1 /FVC < 0.7 but > LLN (ratio-only group) vs subjects without COPD and those with mild or moderate to severe COPD.
the fixed ratio were more likely to die and to have a COPD-related hospitalization during an 11-year follow-up. [16] This finding suggests that a fixed ratio may identify at-risk patients, whereas the LLN may miss a part of the population more likely to have complications and who were not eligible to benefit from intervention. However, the study did not include postbronchodilator spirometry, which is a current requisite for the definition of airflow limitation that is not fully reversible. [6] , [7] There is evidence that 20% to 30% of a population classified as obstructed on the basis of prebronchodilator spirometry will not meet this criterion after an inhaled bronchodilator. [17] , [18] In addition, the fact that the fixed ratio can discriminate risk of death indicates its capacity for identifying a proportion of subjects at risk but does not necessarily reflect the influence of the definition in the clinical characteristics of the disease. Moreover, the fixed ratio misses some young subjects, particularly women, with definite obstruction based on LLN criteria who are likely to benefit from early intervention. [19] The aim of the present study was to determine from a population-based sample the differences in health-related quality of life (HRQL), exacerbations within the previous year, exercise tolerance, physical activity, comorbidity, and systemic inflammatory biomarkers between subjects with an FEV 1 /FVC ratio of < 0.70 but > LLN (ratio-only group) and subjects without COPD (non-COPD group) and those with mild or moderate to severe COPD.
Study Population
We used data from the Epidemiologic Study of COPD in Spain (EPI-SCAN), a multicenter, cross-sectional, population-based, observational study, to estimate the prevalence of COPD. Detailed descriptions of the EPI-SCAN study have been published elsewhere. [20] , [21] For the present study, our source population included 3,802 noninstitutionalized subjects aged 40 to 80 years who completed at least two ATS-acceptable spirometric maneuvers. The study was approved by the corresponding ethics committees (Hospital Clinic; Barcelona, Spain). All subjects gave written informed consent to participate in the study.
Spirometry and Definition of Groups
Spirometries were performed at each site using the same equipment (Master Scope CT; VIASYS Healthcare; Hochberg, Germany) according to the ATS/European Respiratory Society recommendations. [22] Subjects were classified according to the presence of airflow obstruction, which was defined by a postbronchodilator FEV 1 /FVC ratio of < 0.70 or < LLN obtained from Spanish prediction equations. [23] Subjects were included in the ratio-only group if their FEV 1 /FVC was < 0.70 but > LLN. Subjects with an FEV 1 /FVC < LLN were included in the COPD group and stratified into mild or moderate to severe categories according to their predicted FEV 1 . [6] The remaining subjects were assigned to the non-COPD group (Fig 1) .
Figure 1
Composition of study groups. LLN = lower limit of normal.
All subjects with an FEV 1 /FVC ratio < 0.70 were selected for an extended visit. To avoid excessively testing the non-COPD study population, an equal number of subjects from the non-COPD group were consecutively selected, without alternation, in each center.
To control for the effect of comorbidities, additional exclusion criteria for the biomarker analysis included a previous diagnosis of ischemic heart disease, congestive heart failure, cancer, hepatic cirrhosis, chronic renal failure, rheumatoid arthritis, or any other systemic inflammatory disease. In addition, specific exclusion criteria from the non-COPD cohort were respiratory symptoms from the European Coal and Steel Community questionnaire, any associated concomitant disease, and consumption of medication (e- Figure 1 ). The control group selected after applying these criteria was considered to comprise healthy subjects.
Clinical Measures
Demographic characteristics, smoking habits, educational level, domestic and occupational exposures, respiratory history and symptoms, previous medication, and use of health services data were collected. Any respiratory exacerbation that required a change in regular medication was considered to be mild, whereas a respiratory exacerbation treated with a course of oral corticosteroids or antibiotics was considered moderate.
Self-reported comorbidity was documented using the Charlson index. [24] The presence of heart failure, ischemic heart disease, peripheral vascular disease, or cerebrovascular disease was coded as cardiovascular disease. Baseline dyspnea level was assessed by the Modified Medical Research Council scale. The validated Spanish versions of the London Chest Activity of Daily Living scale, the EuroQol 5 Dimensions questionnaire, and the St. George Respiratory Questionnaire (SGRQ) also were administered to assess overall health status.
Six-min walk tests were performed according to the ATS guidelines. [25] To control for a learning effect, two walks were performed with a 30-min rest between walks. Finally, COPD severity was determined by the BMI, degree of airflow obstruction, dyspnea, and exercise capacity (BODE) index. [26] 
Systemic Biomarkers
Serum levels of tumor necrosis factor-ɑ, IL-6, IL-8, C-reactive protein, albumin, fibrinogen, and nitrites/nitrates were determined as previously described. [27] A more detailed description of the applied clinical methods and biomarkers measurement is contained in e-Appendix 1 .
Statistical Analysis
Values are expressed as mean ± SD, mean ± SEM, or percentages. Differences between study groups were analyzed using the χ 2 test or analysis of variance, with post hoc analysis by the Bonferroni test. The effect of any possible confounding factors was assessed using a generalized linear model analysis with adjustment for age, sex, BMI, smoking status (> 10 packs-years, yes or no), and Charlson index.
To examine associations between study groups and comorbidity, ORs in the univariate and multivariate analyses were calculated by logistic regression. We developed multiple logistic regression models with adjustment for age, sex, BMI, smoking habit, and study area (random effect). Statistical significance was assumed for P < .05.
A flow diagram summarizing the distribution of participants and the final study groups is shown in Figure 1 . Subjects in the non-COPD group selected for the extended visit were similar in anthropometric and lung function characteristics to the normal FEV 1 /FVC subject group (e- Table 1 ). Subject characteristics are described in Table 1 . Compared with the non-COPD subject group, the ratio-only subjects were predominantly men; were older; and had larger BMI values, greater cumulative tobacco use, and more frequent comorbidities, especially cardiovascular disease and diabetes mellitus. Interestingly, the ratio-only subjects had a lower inspiratory capacity than those in the non-COPD group (standardized residuals, -1.204 ± 1.756 vs -0.012 ± 1.649; P < .001). The reduction of the inspiratory capacity was significant (> 1.96 standardized residuals) in 49 (34%) ratio-only subjects, which could reflect a certain degree of hyperinflation. Compared with subjects with mild COPD, ratio-only subjects were only older, with no significant differences in sex, pack-years smoking, occupational exposures, and comorbidity. 2.53 ± 0.60 [a] 1.72 ± 0.52 [a] , [b] , [c] < .001 FEV 1 , % predicted 112 ± 16 93 ± 16 [a] 94 ± 9 [a] 63 ± 12 [a] , [b] , [c] < .001
0.68 ± 0.03 [a] 0.61 ± 0.05 [a] , [b] 0.55 ± 0.08 [a] , [b] , [c] < .001 VC, L 3.76 ± 1.07
3.50 ± 0.96 [g] 4.05 ± 1.03 [i] 3.16 ± 0.86 [a] , [c] , [e] < .001
VC, % predicted 108 ± 19 104 ± 20 116 ± 17 [b] , [d] 89 ± 17 [a] , [b] , [ Figure 2 shows the sex and age distribution of the prevalence of overdiagnosed COPD using the fixed ratio and of mild and moderate to severe COPD. The relationship of COPD overdiagnosis with increasing age and male sex can be observed. In addition, the prevalence of overdiagnosed COPD doubles that of mild COPD and becomes even greater in the > 60 age strata.
Figure 2
Distribution of overdiagnosed and severity levels of COPD according to sex and age group. Table 2 shows the adjusted comparison of clinical characteristics, quality of life, daily physical activity, and exercise tolerance obtained among the study groups, after adjusting for sex, age, BMI, smoking intensity, and Charlson index. Compared with subjects in the non-COPD group, the ratio-only subjects had a poorer quality of life, with higher scores in all the domains of the SGRQ and lower visual analog scale scores of the EuroQol 5 Dimensions questionnaire. There were no differences identified between the two groups for respiratory exacerbations, dyspnea, physical activity, or exercise tolerance as evaluated by the 6-min walk distance. In contrast with this comparison, subjects with mild COPD had more moderate respiratory exacerbations and more dyspnea than those without COPD. Except for a poorer score in the symptoms domain of the SGRQ (32.4 ± 2.1 vs 24.3 ± 1.5; P = .008), no differences were identified between the ratio-only subjects and those with mild COPD, respectively (e- Tables 2-4 ). Crude and adjusted relative ORs of comorbidity according the study groups is shown in Table 3 . The crude analysis shows a greater incidence of cardiovascular diseases and diabetes mellitus in the ratio-only group compared with the non-COPD group. Nevertheless, although in the analysis adjusted for age, sex, BMI, and smoking habit the risk for cardiovascular disease persists in the mild and moderate to severe COPD groups, there is no evidence of increased cardiovascular risk in the ratio-only group and no differences for diabetes mellitus. The adjusted model included as covariates age, sex, BMI, and smoking habit.
a Cardiovascular diseases include heart failure, ischemic heart disease, cerebrovascular disease, and peripheral vascular disease.
Systemic inflammatory biomarkers were compared in subgroups obtained after excluding subjects with comorbidities and, in the case of the non-COPD group, those who had respiratory symptoms or used respiratory medication (e- Table 5 ). In Table 4 , the adjusted comparison among the four subgroups is shown. Although the subjects with moderate to severe COPD showed higher levels of C-reactive protein, tumor necrosis factor-ɑ, and IL-6 than the control subgroup, no difference was detected in the serum concentrations of inflammatory biomarkers between the ratio-only group and the control subgroup. At the same time, it is striking that the subjects in the mild COPD subgroup had greater serum concentrations of nitrites/nitrates than the control and ratio-only subgroups. [b] .044
TNF-ɑ, pg/mL 11.1 ± 0.8 10.8 ± 1.4 9.8 ± 1.8 16.9 ± 1.8 [b] , [c] , [d] .017
IL-6, pg/mL 3.91 ± 0.46 3.41 ± 0.77 3.12 ± 1.07 6.92 ± 1.06 [b] , [c] , [d] . NOx, nmol/L 25.9 ± 1.5 26.2 ± 2.5 37.9 ± 3.4 [c] , [e] 30.6 ± 3.3 .008
Data are presented as mean ± SEM. Comparisons between groups by ANOVA with Bonferroni post hoc comparisons. CRP = C-reactive protein; TNF = tumor necrosis factor; NOx = nitrites/nitrates. See Table 2 legend for expansion of other abbreviation.
a Adjusted mean for sex, age, BMI, and smoking habit (> 10 pack-y).
b P < .05 vs control subgroup.
c P < .05 vs ratio-only subgroup.
d P < .05 vs mild COPD subgroup.
e P < .01 vs control subgroup.
Our results show that patients diagnosed as having COPD because of an FEV 1 /FVC ratio of < 0.7 but greater than their LLN have a poorer HRQL than those without COPD, even though they did not show differences in the number of respiratory exacerbations, daily physical activity, comorbidities, exercise tolerance, or systemic inflammatory response.
In our population sample, the overdiagnosis of COPD affected 4.6% of subjects aged 40 to 80 years, which is between one-half and one-third of the COPD prevalence usually reported. [19] , [21] , [28] Our data are concurrent with those reported by Shirtcliffe and coworkers [5] in an urban New Zealand population.
The differences in lung function among study groups deserve further discussion. Generally, it has been considered that the use of a statistically derived LLN seems to be necessary because the FEV 1 declines more rapidly with age than the FVC in normal subjects; thus, the FEV 1 /FVC ratio decreases with age. [19] However, the subjects with mild COPD did not show an FEV 1 (% predicted) lower than the ratio-only subjects, but they did show a greater FVC (% predicted) (Table 1) . Moreover, the identification of a lower inspiratory capacity in some ratio-only subjects poses the possibility that these subjects present a certain degree of hyperinflation. In fact, alterations have been described in resting pulmonary function tests of symptomatic patients with COPD with very early affectation that confirms the existence of significant small airway dysfunction. [29] This functional alteration could potentially be relevant because it has been reported that inspiratory capacity is a powerful functional predictor of all-cause and respiratory mortality and of exacerbation-related hospital admissions in patients with nonsevere COPD. [30] The most important finding of our study is that the ratio-only group had a poorer HRQL than the non-COPD group. This result partially contrasts with the study by Bridevaux et al, [31] who did not find differences in the HRQL between asymptomatic patients with GOLD I COPD from the general population and a reference group, whereas the symptomatic patients did have a poorer quality of life. Regardless of the heterogeneity of the GOLD I group, generic instruments are less sensitive than disease-specific ones, particularly in patients with mild disease. Moreover, their results could be conditioned by the selection of patients according to their respiratory symptoms, which seem to be essential determinants of the HRQL of patients with incipient forms of COPD.
Apart from quality of life, we have found no other differences between the ratio-only and the non-COPD subject groups for respiratory exacerbations, physical activity, exercise tolerance, comorbidities, or systemic inflammation. We have observed, however, that the subjects with mild and moderate to severe COPD had a greater risk of cardiovascular comorbidity. In fact, previous evidence demonstrates that the development of cardiovascular mortality is inversely related to FEV 1 . A prospective study with a 29-year follow-up of the Buffalo Health Study cohort suggested that pulmonary function is a long-term predictor for overall survival rates in both sexes. [32] From a cohort of patients with COPD, it was found that the patients with more severe disease had higher cardiovascular morbidity and mortality than those with less severe disease, particularly arrhythmia, ischemic heart disease, and congestive heart failure. [33] The comparison between the ratio-only and mild COPD groups does not show relevant differences in the quantity of accumulated tobacco use, occupational exposure, number of respiratory exacerbations, or HRQL, except in the symptoms domain of the SGRQ, which showed a higher score in the subjects with mild COPD. This difference may have prognostic relevance because in population-based studies, respiratory symptoms are of major importance for predicting long-term clinical outcomes in subjects with mild COPD. [30] After an 11-year follow-up in patients with mild COPD, Bridevaux and coworkers [31] only identified an accelerated decline in FEV 1 , a greater use of health-care resources, and a poorer HRQL in patients with respiratory symptoms.
Better clinical characterization of the ratio-only subjects and those with mild COPD may provide an additional argument for the choice of the LLN as a diagnostic criterion of COPD. To date, the fixed ratio has been defended because it is easy to remember and calculate, thus helping to remove the barriers to widespread use of spirometry, and is more sensitive than LLN in identifying patients at risk for death and COPD-related hospitalizations. [14] In favor of LLN on the other hand, it is argued that the fixed ratio may misclassify healthy elderly patients as having COPD, thus possibly causing unnecessary treatment, and misclassify as healthy younger patients who are already affected by COPD. [15] In addition, the development of software for most spirometers allows for the LLN to be easily obtained, and the need for reference equations is already established by the COPD severity classification. Our results show that although the subjects misclassified as having COPD by the fixed ratio had a certain degree of deterioration in their quality of life, they had no more respiratory exacerbations, comorbidity, exercise intolerance, or systemic inflammation.
Some limitations of the present study deserve further discussion. Our study may not necessarily represent patients with COPD who are treated at outpatient clinics because the population sampling produces a high level of underdiagnosis and undertreatment. It is necessary to insist once again on the differing approaches of the clinical and epidemiologic perspectives in the debate on COPD diagnosis. Although the two current definitions of COPD are based exclusively on the presence of airflow obstruction assessed by spirometry, the important question for a clinician is the reliability of these two criteria in making the diagnosis in symptomatic individuals, not in those identified by a screening program. Despite the clinical importance of prior probability of the disease presence in interpreting these thresholds, its application to nonselected population samples can provide complementary information on the population repercussions of the disease. In addition, the groups showed differences in recognized risk factors, such as certain anthropometric characteristics and smoking. Although statistical modeling aims to adjust for these possible confounding factors, the existence of some uncontrolled effects cannot be excluded. Further, we cannot rule out that the sample size reached by the distribution of the population sample among the different study groups is not sufficient to detect significant differences in some variables. Thus, it is interesting that the number of exacerbations or hospitalizations, the 6-min walked distance, and the adjusted OR of comorbidities for the ratio-only subjects lie between the values for subjects with no COPD and mild COPD (Tables 2, 3 ). Finally, this study was crosssectional, and inference of causality and prognostic evaluation are not possible.
In conclusion, the use of a 0.7 fixed ratio instead of the LLN of FEV 1 /FVC originates an overdiagnosis of COPD in 4.6% of subjects aged 40 to 80 years. This group of subjects has worse HRQL compared with those without COPD, although they showed neither less tolerance to exercise nor indices of systemic affectation.
